B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained its Buy rating on Alnylam Pharmaceuticals and raised the price target from $295 to $307.
September 04, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has maintained its Buy rating on Alnylam Pharmaceuticals and increased the price target from $295 to $307, indicating confidence in the company's future performance.
The increase in the price target from $295 to $307 by B of A Securities suggests a positive outlook on Alnylam Pharmaceuticals' future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100